EY

EyeGate Pharma

- NASDAQ:EYEG
Last Updated 2022-01-04

LinkedIn Profile

Access EyeGate Pharma historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:eyeg 135892 Jan 4th, 2022 12:00AM EyeGate Pharma (Nasdaq:EYEG) 937 11.00 Open Pharmaceuticals Jan 3rd, 2022 09:40PM Jan 3rd, 2022 09:40PM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma
nasdaq:eyeg 135892 Jan 3rd, 2022 12:00AM EyeGate Pharma (Nasdaq:EYEG) 936 11.00 Open Pharmaceuticals Jan 3rd, 2022 09:06AM Jan 3rd, 2022 09:06AM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma
nasdaq:eyeg 135892 Jan 2nd, 2022 12:00AM EyeGate Pharma (Nasdaq:EYEG) 936 11.00 Open Pharmaceuticals Jan 2nd, 2022 03:41PM Jan 2nd, 2022 03:41PM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma
nasdaq:eyeg 135892 Jan 1st, 2022 12:00AM EyeGate Pharma (Nasdaq:EYEG) 936 11.00 Open Pharmaceuticals Jan 1st, 2022 05:33PM Jan 1st, 2022 05:33PM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma
nasdaq:eyeg 135892 Dec 31st, 2021 12:00AM EyeGate Pharma (Nasdaq:EYEG) 936 11.00 Open Pharmaceuticals Dec 31st, 2021 01:55PM Dec 31st, 2021 01:55PM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma
nasdaq:eyeg 135892 Dec 30th, 2021 12:00AM EyeGate Pharma (Nasdaq:EYEG) 936 11.00 Open Pharmaceuticals Dec 30th, 2021 12:25PM Dec 30th, 2021 12:25PM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma
nasdaq:eyeg 135892 Dec 29th, 2021 12:00AM EyeGate Pharma (Nasdaq:EYEG) 936 11.00 Open Pharmaceuticals Dec 29th, 2021 12:47PM Dec 29th, 2021 12:47PM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma
nasdaq:eyeg 135892 Dec 28th, 2021 12:00AM EyeGate Pharma (Nasdaq:EYEG) 936 11.00 Open Pharmaceuticals Dec 28th, 2021 09:22AM Dec 28th, 2021 09:22AM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma
nasdaq:eyeg 135892 Dec 27th, 2021 12:00AM EyeGate Pharma (Nasdaq:EYEG) 936 11.00 Open Pharmaceuticals Dec 27th, 2021 11:35AM Dec 27th, 2021 11:35AM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma
nasdaq:eyeg 135892 Dec 26th, 2021 12:00AM EyeGate Pharma (Nasdaq:EYEG) 936 11.00 Open Pharmaceuticals Dec 26th, 2021 03:06PM Dec 26th, 2021 03:06PM Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients. Open Pharmaceutical research and development, eye disease, eye disorders, ophthalmology, ophthalmic drugs, anterior uveitis, cataract surgery, Clinical trials, ocular disease, corneal disease, superficial punctate kertopathy Open 271 Waverley Oaks Rd Waltham MA US 02452 EyeGate Pharma

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.